IMUC (EOM Pharmaceutical Holdings) 3-1 Month Momentum %: 30.43% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings 3-1 Month Momentum %?

EOM Pharmaceutical Holdings IMUC 3-1 Month Momentum % is 30.43% as of Aug. 20, 2026.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), EOM Pharmaceutical Holdings's 3-1 Month Momentum % is 30.43%.

The industry rank for EOM Pharmaceutical Holdings's 3-1 Month Momentum % or its related term are showing as below:

IMUC's 3-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -5.39 vs IMUC: 30.43

EOM Pharmaceutical Holdings  (OTCPK:IMUC) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

EOM Pharmaceutical Holdings 3-1 Month Momentum % Related Terms

IMUC vs MNTMD, RTTR, BZYR: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EOM Pharmaceutical Holdings 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's 3-1 Month Momentum % falls into.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 30.43% mean?
EOM Pharmaceutical Holdings (IMUC) has a 3-1 Month Momentum % of 30.43% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' 3-1 Month Momentum % too high?
EOM Pharmaceutical Holdings' current 3-1 Month Momentum % is 30.43%.
How does EOM Pharmaceutical Holdings' 3-1 Month Momentum % compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' 3-1 Month Momentum % of 30.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current 3-1 Month Momentum % is 30.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current 3-1 Month Momentum % of 30.43%. The current 3-1 Month Momentum % is 30.43%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current 3-1 Month Momentum % is 30.43% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.